Novavax Inc and its partner Serum Institute of India on Thursday said they have submitted an application to the World Health Organization for emergency use listing (EUL) of Novavax's COVID-19 vaccine.
The Serum Institute of India has informed the Centre that it will be able to supply around 22 crore doses of Covishield in October
Difference between the effectiveness of a single dose versus two doses is not that large for protection from hospitalisation and severe disease.
Sources say the Centre has been working to create a stockpile of vaccines for India in case a third wave strikes
The Union government has placed a purchase order with the Serum Institute of India (SII) for 66 crore doses of Covishield to be supplied by December, official sources said on Thursday. The development comes after Prakash Kumar Singh, the Director, Government and Regulatory Affairs at SII, informed the Union Health Ministry that the firm would be able to supply 20.29 crore doses of Covishied in the month of September. The Pune-based firm has enhanced the manufacturing capacity of Covishield to more than 20 crore doses per month. The Health Ministry had in July placed an order with Bharat Biotech for the supply of 28.50 crore doses of Covaxin, but the firm has not been able to start the supply of those yet, an official source said. Bharat Biotech is close to completing the supply of five crore doses of Covaxin for which the Health Ministry had placed an order on March 12, the source said. The source added that the ministry had placed an order for 37.50 crore doses of Covishield betw
The Kerala High Court has directed the Centre to allow scheduling, on CoWIN portal, of second COVISHIELD dose after four weeks from the first for those who want to take it earlier
In a crucial intervention, the Kerala High Court on Monday ruled that the second dose of Covishield can be taken 28 days of taking the first dose in the private sector
After donating or selling 66 million doses to nearly 100 countries, India barred exports in the middle of April to focus on domestic immunisation as infections exploded
Earlier there were reports that government could make a move to reduce the minimum gap between two doses of the Covishield Covid-19 vaccine, but NTAGI has denied the reports
SII has informed the Centre that it will be able to supply around 20 crore doses of COVID-19 vaccine Covishield in September itself to Government to India and private hospitals, official sources said
Deal value not disclosed; former co-promoters Kaisha exits JV
SII, the world's largest vaccine maker by production volume, has taken a 50% stake in Indian drug vial maker Schott Kaisha, the companies said in a statement on Tuesday.
The joint venture is for pharmaceutical packaging
Serum Institute of India (SII) chairman Dr Cyrus Poonawalla on Friday said he was not in favour of administering two different coronavirus vaccines for better efficacy. Poonawalla, whose firm makes the Covishield vaccine, was speaking to reporters after receiving the Lokmanya Tilak National Award here. "I am against the mixing of two different vaccines. There is no need to mix two different vaccines," he said, when asked about a recent ICMR study that a cocktail of Covishield and Covaxin could generate better immunity. "If cocktail vaccines are administered and if the result is not good, then SII may say that another vaccine was not good, vice versa, the other company might say that since you mixed Serum's vaccine, it did not give desired results," Poonawalla said. The efficacy of this approach has not been proven in field trials involving thousands of participants, he added. A study by the Indian Council of Medical Research involving 98 people, 18 of whom had inadvertently ...
Cyrus Poonawalla, chairman of SII, on Friday termed the ban on Covid-19 vaccine exports imposed by the Union government a very bad move, saying it put his company,in a difficult situation
Chairman of vaccine maker Serum Institute of India (SII), Dr Cyrus Poonawalla, on Friday hailed the Modi government saying that red-tapism and licence raj have come down under its rule.
SII and Novavax have now completed submission of all modules required by regulatory agencies in India, Indonesia and the Philippines for the initiation of review of the vaccine
The study was conducted on 18 individuals who inadvertently received Covishield as first jab and Covaxin as second in UP at a gap of six weeks
Study also found that the combination was safe and adverse effects were found to be similar when compared to the same-dose regimen
Poonawalla met Home Minister Amit Shah in Parliament and the meeting between the two lasted for 30 minutes.